Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males With Duchenne Muscular Dystrophy (DMD)

Next Previous
Trial Profile

A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males With Duchenne Muscular Dystrophy (DMD)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RGX 202-REGENXBIO (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man; Pharmacodynamics; Registrational
  • Acronyms AFFINITY DUCHENNE
  • Sponsors REGENXBIO

Most Recent Events

  • 06 Nov 2025 According to a REGENXBIO media release, the data from the trial were presented at the International Congress of the World Muscle Society
  • 30 Oct 2025 According to a REGENXBIO media release, the pivotal portion of the multi-center, open-label Phase I/II/III AFFINITY DUCHENNE trial completed enrollment of 30 participants in October 2025; the company expects sharing topline pivotal data in early Q2 of next year
  • 29 Sep 2025 According to a REGENXBIO media release, the data from the trial will be presented at the International Congress of the World Muscle Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top